In a significant move towards entering the cardiovascular and chronic kidney disease space, Novo Nordisk has agreed to acquire late-stage investigational drug, ocedurenone, from KBP Biosciences for up to US$1.3 B. The drug is currently in Phase III development for uncontrolled hypertension and has a potential application in cardiovascular and kidney disease. This acquisition is closely aligned with Novo’s strategic focus on expanding beyond its core business in diabetes and venturing into other serious chronic diseases, including through novel drug modalities.